Aardvark Therapeutics, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | – | |
| – | -11.8% | -83.5% | -8,262.5% | |
| – | -24.0% | +40.3% | +799.3% | |
| – | – | – | -77.4% | |
| – | – | – | -12.8% | |
| – | – | – | +314.0% | |
| – | – | – | – | |
| – | -100.0% | – | +8.9% | |
| – | – | – | -128.1% | |
| – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.